



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Val Sheffield et al.

Serial No.: 10/025,187

Filed: December 18, 2001

For: A BARDET-BIEDL SUSCEPTIBILITY
GENE AND USES THEREOF

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: IOWA:034US

PATENT

1645
#5
CO
2-12-03
RECEIVED
JAN 27 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: <u>Box DD, Commissioner for Patents, Washington, DC 20231</u> , on the date below:	
January 23, 2003	
Date	Steven L. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX DD

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be


25240008.1

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:034US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 23, 2003

Form PTO-1449 (modified)

Atty. Docket No.
IOWA:034USSerial No.
10/025,187

List of Patents and Publications for Applicant's

Applicant
Val Sheffield *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 18, 2001Group:
1645U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 01 00825 A2	1-4-01	PCT			
	B2	EP 1 074 617	2-7-01	Europe			
	B3	WO 00 35937	6-22-00	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	Hoang et al., "Cloning of a novel c-terminal kinesin (KIFC3) that maps to human chromosome 16Q13-Q21 and thus is a candidate gene for Bardet-Biedl syndrome," <i>Genomics</i> , 52:219-222, 1998.

25250708.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Copied from 10025185 on 18-11-2003